< Back to latest news & events

News

EPO continues oral proceedings by videoconference in examination and opposition during pendency of referral G 1/21

March 2021

The EPO Boards of Appeal took the decision that from the start of 2021, all Boards of Appeal oral proceedings could be held by videoconference, even if the parties to the proceedings were not in agreement (ostensibly aping the position before Opposition and Examining Divisions).

This decision has been divisive since many believe that holding proceedings by video conference does not give either appellants or respondents the best chance of presenting their case.

On 12 March 2021, Technical Board of Appeal 3.5.02 in appeal case T1807/15 made a referral to the Enlarged Board of Appeal seeking to clarify whether, in view of Article 116(1) EPC, oral proceedings may be conducted by videoconference (VICO) without all parties’ consent. The referral concerns appeal proceedings, but also extends to oral proceedings by VICO before examining and opposition divisions.

The following question was referred to the Enlarged Board of Appeal (G 1/21):

“Is the conduct of oral proceedings in the form of a videoconference compatible with the right to oral proceedings as enshrined in Article 116(1) EPC if not all of the parties to the proceedings have given their consent to the conduct of oral proceedings in the form of a videoconference?”

The Enlarged Board of Appeal will consider the referral on 28 May 2021.

The EPO has today stated that during pendency of the referral, oral proceedings before examining and opposition divisions will continue to be held by VICO as under current practice – that is, without requiring explicit agreement of the parties.  The statement from the EPO does not explicitly mention oral proceedings before the Boards of Appeal however.  It is therefore arguable that the EPO would consider a request for a stay of proceeding in light of the pending referral G 1/12.

This article was prepared by HGF Partner Dr Chris Moore. If you would like further advice on this or any other matter, please contact Chris. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article